New steroid shot may delay chemo in tough prostate cancer
NCT ID NCT07161778
First seen Nov 01, 2025 · Last updated May 03, 2026 · Updated 20 times
Summary
This study tested a steroid called triamcinolone, given as a shot, in 55 men with castration resistant prostate cancer (cancer that no longer responds to standard hormone therapy). The goal was to see if it could control the cancer longer than current steroid pills, which typically work for about 4 months. By delaying the need for chemotherapy, the treatment aims to maintain quality of life in older patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Raigmore Hospital
Inverness, United Kingdom
-
Royal Sussex County Hospital
Brighton, United Kingdom
-
St Bartholomew's Hospital
London, United Kingdom
Conditions
Explore the condition pages connected to this study.